BRUSELAS, 2 Ago. (EUROPA PRESS) –
The European Commission reported this Tuesday the signing of a joint purchase contract with the pharmaceutical company Hipra Human Health to ensure the supply of 250 million doses of its protein vaccine against the coronavirus, ‘Hipra’.
A total of 14 Member States will participate in this joint purchase, the value of which has not been reported by Brussels. Under this agreement, 250 million vials of this protein vaccine will be supplied, which will be developed as a booster dose for previously immunized people over 16 years of age.
Given the increase in COVID infections in Europe, “we must guarantee maximum preparation as we approach the autumn and winter months,” Health Commissioner Stella Kyriakides said in a statement.
This vaccine is currently under evaluation by the European Medicines Agency (EMA), so if marketing authorization is received, participating countries will be able to purchase the vaccine through this current contract.
The vaccine joint purchase agreement with Hipra complements the contracts previously signed with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica, BioNtech-Pfizer, Moderna, Novavax and Valneva, securing some 4.2 billion doses for the EU market in the framework of the COVID vaccination strategy.
Participating countries could decide to donate the vaccines to low- and middle-income countries or redirect them to other European countries.
–
